Medicine for treating infantile asthma

A technology for pediatric asthma and medicine, applied in the field of medicine, can solve the problem of difficult to apply medicine to infants and young children, and achieve the effect of avoiding oral or spray medicine

Pending Publication Date: 2022-03-22
MUDANJIANG MEDICAL UNIV
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this patent is not developed for children with asthma, so it is difficult to apply it to infants and young children

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating infantile asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1: preparation pharmaceutical preparation

[0022] Take 100g of silica gel, 400mg of albuterol, 3g of oleic acid, and 10mg of rose essential oil. First, mix the oleic acid and rose essential oil evenly, then add albuterol, mix well, and roll the silica gel with an open mill to form a special powder. Silica gel.

[0023] Cut the special silica gel into strip-shaped silica gel sheets, the length of the strip-shaped silicone rubber sheets is 240mm, the width is 5mm-50mm, the thickness is 1mm-2mm, and each strip of silica gel sheet weighs 5.5g.

Embodiment 2

[0028] Embodiment 2: drug stability test

[0029] The pharmaceutical preparation obtained in Example 1 was placed in an environment of 25°C and RH60% according to the commercially available packaging, and samples were taken at the 0, 3, 6, 9, 12, 18, and 24 months respectively to check for salbutamol, related substances, etc. Quality indicators, the results are shown in Table 1.

[0030] Table 1 Long-term test results of pharmaceutical preparations

[0031] time (month) Salbutamol content (%) relative substance(%) 0 100 0.18 3 100.89 0.24 6 100.12 0.28 9 100.04 0.30 12 100.31 0.34 18 100.49 0.35 24 100.84 0.42

[0032] The results show that the pharmaceutical preparation of the present invention is placed in an environment of 25° C. and RH60% for 36 months according to the commercially available package, and all indicators have no obvious changes compared with 0 months, and the quality is stable and reliable, which m...

Embodiment 3

[0033] Embodiment 3: pharmacokinetic experiment

[0034] 40 healthy volunteers were divided into 4 groups, among which the silicone sheets of Example 1, Comparative Example 1 and Comparative Example 2 were worn on the left wrists as bracelets in three groups. Another group took commercially available albuterol sustained-release tablets (each containing 8 mg albuterol). Then, collect 1ml of venous blood every hour, and measure its salbutamol blood drug concentration, and the experimental results are as follows: figure 1 shown.

[0035] From the experimental results, the four groups of T max All between 4 hours and 5 hours, but the blood concentration of Comparative Example 1 and Comparative Example 2 is obviously low, which shows that it is difficult for albuterol to achieve Adequate transdermal absorption. Compared with the oral albuterol sustained-release tablets, the blood concentration of Example 1 is slightly lower within 1-5 hours, but the blood concentration is high...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
widthaaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention relates to a medicine for treating infantile asthma, the medicine is a silica gel bracelet, and the silica gel bracelet contains salbutamol as an active component, oleic acid as a penetration enhancer and rose essential oil. Through combination of oleic acid and rose essential oil, transdermal absorption of salbutamol in the silica gel bracelet is facilitated, and the rose essential oil can also be used as an aromatic component to improve the accepting degree of the bracelet by infants. The medicine disclosed by the invention can slowly release salbutamol in a long-acting manner, can avoid oral administration or jet administration, and is beneficial to acceptance of infants.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a medicine for treating Meniere's disease and its application. Background technique [0002] Asthma is a lung disease characterized by reversible airway obstruction, airway inflammation, and increased airway reactivity to multiple stimuli. Airway obstruction in asthma is caused by a combination of factors, including: airway smooth muscle spasm , airway mucosal edema, increased mucus secretion, airway wall cell infiltration, airway epithelial injury and desquamation. [0003] Asthma in children is a common pulmonary disease in children. It is a reversible and obstructive respiratory disease characterized by recurrent cough, wheezing and dyspnea, accompanied by airway hyperresponsiveness. [0004] Salbutamol, a short-acting β2 adrenergic receptor agonist, is used as an antiasthmatic drug, which can effectively inhibit the release of allergenic substances such as hista...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K31/137A61K47/12A61K47/44A61M35/00A61P11/06
CPCA61K31/137A61K9/0014A61K47/44A61K47/12A61P11/06A61M35/10
Inventor 蔡冰冰房丽丽冯淑香董莉乔霜张宇
Owner MUDANJIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap